It is with great pride and joy that we announce the success of our institution. The Faculty of Pharmacy at Jagiellonian University Medical College is a key scientific partner in a strategic project that has secured over PLN 91.7 million in funding from the European Funds for a Modern Economy (FENG) programme. As part of this endeavor, our Faculty will directly receive PLN 5,334,081 to carry out groundbreaking research tasks.

The total value of the project, conducted in a consortium with the Polish biotechnology leader, Selvita S.A., amounts to nearly PLN 200 million.

A Shared Mission: Innovative Therapies of the Future

The official title of the project is: “Increasing the potential and competitiveness of the Polish economy in the field of innovative therapies and drugs of the future, through the development of a Research and Development Centre and the development of research methods and tools, as a response to social needs in the area of public health.”

The project consists of two main modules:

• An infrastructure module – carried out by Selvita S.A., involving the construction of a second, state-of-the-art Research and Development Centre (Hexagon 2) in Krakow for 250 scientists.
• A research module – carried out jointly by Selvita S.A. and our Faculty, focused on developing innovative methods and tools for drug discovery.

The Key Research Role of the Faculty of Pharmacy UJ CM

Our scientific team will play a central role in implementing the first, crucial innovation within the research module. Our task will be:

• To investigate the application of a new element with high therapeutic potential in the drug discovery process.
• To develop a novel research methodology for obtaining compounds of key importance in the therapy of cancer, inflammatory, and autoimmune diseases.

This methodology will cover the entire research process: from the synthesis and purification of compounds, through testing their activity, to the analysis of pharmacokinetic parameters and toxicity. The dedicated funding of over PLN 5.3 million will enable the achievement of these ambitious goals using top-class equipment and research facilities.

The research module will be carried out at the Chair of Pharmaceutical Chemistry of the Faculty of Pharmacy UJ CM and the Laboratory of Pharmacokinetics and Preliminary Toxicology Research (LFWBT) of the Center for the Development of Therapies for Civilization and Age-Related Diseases (CDT-CARD).

– Obtaining funding in such a difficult and prestigious competition is a perfect example of the harmonious cooperation between business and science in the extremely demanding area of new drug development. The collaboration with Selvita, one of the most recognizable Polish biotechnology companies, undoubtedly confirms the high quality of research conducted at UJ CM, and the project’s implementation will bring benefits to both the company and the university – emphasizes Prof. Krzysztof Kamiński from the Chair of Pharmaceutical Chemistry, the project manager at UJ CM.

Participation in such a prestigious and well-funded project is a testament to the highest recognition of the competence and scientific potential of the Faculty of Pharmacy UJ CM. This collaboration is a milestone in building synergy between science and industry, strengthening Krakow’s position as a European capital of pharmaceutical innovation.